Peptide ligands for binding to EphA2
A peptide ligand specific for EphA2 comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.
1. A peptide ligand specific for EphA2 comprising a polypeptide comprising a sequence:
[β-Ala][Sar] 10 H[dD]VPA 1 PWGPFWA 2 PVNRPGA 3 ; or
[β-Ala][Sar] 10 H[dD]VPA 1 [Aib][1Nal]G[Aib]F[1Nal]A 2 P[tBuGly]N[HArg]P[dD]A 3 ;
wherein A 1 , A 2 , and A 3 each represent independently a residue selected from the group consisting of cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap), and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of the A 1 , A 2 , and A 3 is selected from the group consisting of Dap, N-AlkDap, and N-HAlkDap, the A 1 , A 2 , and A 3 residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold;
wherein Aib represents aminoisobutyric acid, 1Nal represents 1-naphthylalanine, tBuGly represents tert-leucine, Sar represents sarcosine, HArg represents homoarginine, and dD represents D-aspartic acid.
2. The peptide ligand as defined in claim 1 , wherein two of A 1 , A 2 and A 3 are selected from the group consisting of Dap, N-AlkDap, and N-HAlkDap, and the third one of A 1 , A 2 and A 3 is cysteine.
3. The peptide ligand as defined in claim 1 , wherein A 1 , A 2 and A 3 are each N-AlkDap or N-HAlkDap.
4. The peptide ligand as defined in claim 1 , wherein the molecular scaffold is an aromatic molecular scaffold.
5. The peptide ligand as defined in claim 4 , wherein the peptide ligand comprises an amino acid sequence selected from the group consisting of:
AF488-(β-Ala)-Sar 10 -H(D-Asp)VPCPWGPFWCPVNRPGCA; and
(β-Ala)-Sar 10 -H(D-Asp)VP-CPWGPFWCPVNRPGC,
or a pharmaceutically acceptable salt thereof, with the proviso that one or more of the cysteine residues in said amino acid sequence is replaced by Dap, N-AlkDap or N-HAlkDap.
6. The peptide ligand as defined in claim 4 , wherein the aromatic molecular scaffold is 1,3,5-tris(methylene)benzene.
7. The peptide ligand as defined in claim 1 , wherein A 2 is cysteine and A 1 and A 3 are each independently Dap, N-AlkDap or N-HAlkDap.
8. The peptide ligand as defined in claim 7 , wherein A 1 and A 3 are Dap.
9. The peptide ligand as defined in claim 1 , wherein the molecular scaffold is a non-aromatic molecular scaffold.
10. The peptide ligand as defined in claim 9 , wherein the non-aromatic molecular scaffold is 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA).
11. The peptide ligand as defined in claim 1 , wherein the EphA2 is human EphA2.
12. The peptide ligand as defined in claim 1 , wherein the peptide ligand is selective for human EphA2, but does not cross-react with human EphA1, EphA3 or EphA4.
13. The peptide ligand as defined in claim 1 , wherein one of A 1 , A 2 and A 3 is selected from the group consisting of Dap, N-AlkDap, and N-HAlkDap.
14. The peptide ligand as defined in claim 1 , wherein the peptide ligand comprises an amino acid sequence selected from the group consisting of:
[β-Ala][Sar] 10 H[dD]VP[Dap]PWGPFW[Dap]PVNRPGC;
[β-Ala][Sar] 10 H[dD]VPCPWGPFW[Dap]PVNRPG[Dap];
[β-Ala][Sar] 10 H[dD]VP[Dap]PWGPFWCPVNRPG[Dap];
[β-Ala][Sar] 10 H[dD]VP[Dap][Aib][1Nal]G[Aib]F[1Nal][Dap]P[tBuGly]N[HArg]P[dD]C;
[β-Ala][Sar] 10 H[dD]VPC[Aib][1Nal]G[Aib]F [1Nal][Dap]P[tBuGly]N[HArg]P[dD][Dap]; and
[β-Ala][Sar] 10 H[dD]VP [Dap][Aib][1Nal]G[Aib]F [1Nal]CP[tBuGly]N[HArg]P [dD][Dap],
or a pharmaceutically acceptable salt thereof.
15. A drug conjugate comprising a peptide ligand as defined in claim 1 , conjugated to one or more effector and/or functional groups.
16. The drug conjugate as defined in claim 15 , wherein said effector and/or functional groups comprise a cytotoxic agent selected from the group consisting of DM1 and MMAE.
17. The drug conjugate as defined in claim 16 , wherein the cytotoxic agent is MMAE.
18. A pharmaceutical composition which comprises the drug conjugate of claim 15 , in combination with one or more pharmaceutically acceptable excipients.
19. A pharmaceutical composition which comprises the peptide ligand of claim 1 , in combination with one or more pharmaceutically acceptable excipients.